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Background: The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-
associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers
(NSCLCs) as oncogenic driver mutations. It has been suggested that EML4-ALK fusion is associated with the resistance
in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib.
In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with
EML4-ALK. Thus, characterization of EML4-ALK fusion genes and clinical features of resulting carcinomas would be a
great benefit to disease diagnosis and designing customized treatment plans. Studies have suggested that EML4-ALK
translocation occurs more frequently in never-smokers with NSCLC, especially in female patients. However, it is not
clear whether this is the case in male patients, too. In this study, we have determined the frequency of EML4-ALK
translocation in male never-smokers with NSCLC in a cohort of Chinese patients. The clinical features associated with
EML4-ALK translocation were also investigated.
Methods: A cohort of 95 Chinese male never-smokers with NSCLC was enrolled in this study. EML4-ALK fusion genes
were detected using one-step real time RT-PCR and DNA sequencing. We further determined the expression levels of
ALK mRNA by RT-PCR and ALK protein by immunohistochemistry in these specimens. The clinical features of EML4-
ALK–positive carcinomas were also determined.
Results: We have identified EML4-ALK fusion genes in 8 out of 95 carcinoma cases, accounting for 8.42% in Chinese
male never-smokers with NSCLC. It is significantly higher than that in all Chinese male patients (3.44%) regardless
smoking habit. It is also significantly higher than that in all Chinese smokers (8/356 or 2.25%) or in smokers worldwide
(2.9%) by comparing to published data. Interestingly, EML4-ALK fusion genes are more frequently found in younger
patients and associated with less-differentiated carcinomas.
Conclusions: The frequency of EML4-ALK translocation is strongly associated with smoking habits in Chinese male
patients with higher frequency in male never-smokers. EML4-ALK translocation is associated with early-onset and
less-differentiated carcinomas.
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Table 1 Clinical characteristics of 95 Chinese male
never-smokers with NSCLC
Characteristics No. (patients) % (patients)




Differentiation poor 31 32.63%
moderate 39 41.05%
well 25 26.32%
Histology Adenocarcinoma 84 88.42%
Squamous 6 6.32%
Others 5 5.26%
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Lung cancer is one of the most common cancers and is by
far the leading cause of cancer-related deaths worldwide
[1]. Nearly 80% of lung cancer patients are diagnosed as
non-small cell lung cancer (NSCLC) at advanced stages of
the disease [2]. The average survival time is usually short
after diagnosis, largely due to unsatisfactory outcomes
from conventional chemotherapeutic regimens, especially
in patients with metastatic cancer [3]. However, the treat-
ment outcome has been improved significantly in the past
several years owing to increased understanding on mo-
lecular mechanisms of tumorigenesis. It is highlighted by
the finding that the epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR TKIs) including gefitinib and
erlotinib have shown superior improvement on survival
time and life quality in a subset of patients harboring
EGFR activating mutations [4,5]. Thus, current strategies
to improve treatment outcomes have been focused on
target-specific and customized treatment according to the
patient’s molecular profile [6].
The fusion of the anaplastic lymphoma kinase (ALK)
with the echinoderm microtubule-associated protein-like
4 (EML4) on chromosome 2p was first identified as onco-
genic driver mutations in 2007 in Japanese NSCLC pa-
tients [7]. Out of 75 examined Japanese patients, 5
patients (6.7%) were found carrying the EML4–ALK fusion
transcript, which resulted from a small inversion within
chromosome 2p [7]. Multiple studies have been carried
out to determine the frequency of EML4–ALK transloca-
tion occurrences in patients with NSCLC, ranging from
1.6% to 11.7% in individual studies [7-18] with an averaged
frequency at about 5%, estimated from published results
[6]. The huge variation among these studies is likely due
to the differences in patient selection criteria such as dis-
ease status, race, country, gender, and/or smoking habit.
Other ALK-fusion genes including KIF5B-ALK have also
been identified in patients with NSCLC [8,19-21]. It has
been suggested that patients with ALK rearrangement are
resistant to EGFR TKIs [22]. However, crizotinib (XALK-
ORI®, Pfizer Inc.), an ALK tyrosine kinase activity inhibitor,
has been approved by the FDA in the United States for
treating patients with ALK + advanced NSCLC [23] as well
as in other countries, including China.
Although EML4–ALK translocation was first identified
from a lung adenocarcinoma specimen surgically resected
from a 62-years-old man with a history of smoking [7], in-
creased evidence suggests that it is much more common
in never-smokers based on the studies performed in dif-
ferent countries [10,15,16,22]. As estimated, the incidence
of EML4-ALK fusion in never-smokers is 9.4% vs. 2.9% in
smokers [6]. In addition to smoking habit, studies also
suggest that the frequency of the incidence is different
between male and female patients [17,18]. However, based
on the available data from these publications, it is notclear what the frequency is in either male or female never
smokers who were diagnosed as NSCLC. A recent study
has reported that the incidence could be as high as 15.2%
(5/33) in a small cohort of Chinese female adenocarcin-
oma patients who are never-smokers [18]. However, it is
not clear whether the incidence is also high in male never-
smokers with NSCLC. To address this question, we as-
sembled 95 Chinese male patients who are never smokers
and diagnosed with NSCLC. We used one-step reverse
transcription polymerase chain reaction (RT-PCR) to
screen ELM4-ALK fusion genes in these patients. We have
identified 8 (8.42%) cases with ALK rearrangement, which
is significantly higher than estimated 2.9% in the smokers
with NSCLC worldwide [6]. Interestingly, our study sug-
gests that EML4-ALK rearrangements in Chinese male
never-smokers with NSCLC are more frequently detected
in younger patients and in less-differentiated carcinomas.
Methods
Patient enrollment and tissue specimens
There are a total of 95 non-smoking Chinese male patients
with NSCLC enrolled in this study (Table 1). These
patients are from Shengjing Hospital of China Medical
University, Hunan Cancer Hospital, Henan Cancer Hos-
pital, China. All participants who underwent surgery pro-
vided written informed consent. The study was approved
by the Institutional Ethics Committee of Henan Cancer
Hospital. Tissue specimens, which were collected from
NSCLC patients with suspected NSCLC, were preserved in
formalin-fixed paraffin-embedded (FFPE) tissue blocks.
These FFPE tissue blocks were subjected to EML4-ALK
detection, mRNA and protein level evaluation, and fluores-
cence in situ hybridization (FISH) analysis. Tumor subtype
and pathological characteristics were evaluated independ-
ently by two pathologists as a standard procedure during
disease diagnosis. In cases with diagnostic disagreement, a
third pathologist gave additional independent review.
Depending on how closely the cancer cells and tissue
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a three-tiered grading system as well differentiated (Grade
1), moderately differentiated (Grade 2), and poorly differ-
entiated (Grade 3). Grade 1 (low grade) tumors appear
close to normal and tend to grow and spread slowly. Grade
2 and 3 tumors look abnormal and tend to grow more
rapidly and spread faster than tumors with a lower grade.
Collectively, Grade 2 and 3 tumors are described as less-
differentiated carcinomas.
Identification of EML4-ALK fusion gene
FFPE tissue blocks were sectioned onto slides for
hematoxylin and eosin (H&E) staining. The sections for
further study were left unstained. Tumor areas were
identified and collected for RNA extraction as described
below. Total RNA was extracted with RNeasy FFPE Kit
(Qiagen, CA, USA) following the manufacturer’s instruc-
tions. Extracted RNA samples were treated with DNase I
(DNA-free; Applied Biosystems-Ambion, TX, USA) to
remove any DNA contamination before one-step RT-
PCR. These RNA samples were then subjected to one-
step RT-PCR to detect EML4-ALK fusion transcripts
using human Lung Cancer Related Fusion Gene Detec-
tion Kit (fluorescence RT-PCR) (Shanghai Yuanqi Bio-
Pharmaceutical Co., Ltd.). The sequences of the PCR
primers as well as DNA sequencing primers are shown
in Table 2. RT-PCR was also performed using a different
set of primers that were previously published [24]. The
mixture of each reaction contains 3 μL total RNA, 20 μL
Multiplex RT-PCR Buffer, 2 μL Multiplex Enzyme Mix
in a total volume of 25 μL. The RT-PCR was performedTable 2 Sequences of primers used for detection of
subtypes of EML4-ALK fusion
Forward primers















E15-A20 (V4a) EML4-E15 GTAGCAGAAGGAAAG
GCAGATC
E17-A20, E18-A20 (V9) EML4-E17 CGCTACTCAATAGATG
GTACCT
E20-A20 (V2) EML4-E20 CGGGAGACTATGAAATA
TTGTACT
Common reverse primer ALK-E20 CATGATGGTCGAGGTG
CG C
Sequencing primer TTGCTCAGCTTGTACTCA
GGGCTCTGat 42°C for 30 min, at 94°C for 5 min followed by 40 cy-
cles 94°C for 15 s and 60°C for 1 min on the 7300 Real
Time PCR System (ABI, USA). All positive cases identi-
fied by RT-PCR were confirmed by both DNA sequen-
cing and Vysis ALK Break Apart FISH analysis.
ALK tyrosine kinase expression analysis
Primers specific to ALK tyrosine kinase domain (ALK
TK) were designed for ALK mRNA expression analysis.
The expression level of housekeeping gene ABL was also
determined as the control. The primers used for ALK




CA-3′. The DNA sequencing primers include ALK-se-
quencing primer 5′-CCCTTTCTATAGTAGCTCGCCC
TGTAGAT-3′ and ABL-sequencing primer 5′-CCATG
TACAGCAGCACCACGGCGT-3′.
The expression of ALK tyrosine kinase was examined
by immunohistochemistry using rabbit monoclonal
antibody against ALK (clone D5F3, Cell Signaling Tech-
nology, Inc., USA), which detects endogenous levels of
total ALK protein as well as ALK fusion proteins. The
experiments were performed on FFPE sections, as de-
scribed in detail previously [25]. In brief, after deparaffi-
nization, tissue sections were incubated with 3% H2O2
to block endogenous peroxidase activity. Heat-induced
antigen retrieval was then performed for 30-60 minutes
using the Ventana CC1 mild reagent containing a com-
bination of ethylenediaminetetraacetic acid (EDTA) and
boric acid in Tris buffer (Ventana Medical Systems,
Inc., USA). After blocking with 10% normal goat serum,
the abovementioned rabbit monoclonal antibody against
ALK (D5F3) was applied, followed by incubation with
horseradish peroxidase-conjugated multimer antibody
(Ventana Medical Systems). The antigen-antibody com-
plex was visualized using diaminobenzidine (UltraView,
Ventana Medical Systems) and the slides were slightly
counterstained with hematoxylin. Slides were evaluated
for intensity (0 no staining; 1+ light staining; 2+ moder-
ate staining; 3+ strong staining) and distribution of ALK
immunostaining. Any IHC intensity greater than 0 was
defined as IHC positive.
ALK Break Apart FISH analysis detecting ALK
rearrangement
To identify ALK rearrangements, FISH experiments were
performed on FFPE tissue sections by using Vysis ALK
Break Apart FISH Probe Kit (Abbott Molecular Inc.,
USA) according to vendor’s instruction. In brief, DNA
probes that flank the ALK breaking point and are labeled
with green and red florescent dye separately were used in
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Figure 1 Screening for EML4-ALK fusion genes in Chinese male
never-smokers with NSCLC. (A) DNA gel electrophoresis showing
the expression of EML4-ALK fusion genes (top panel) and ABL controls
(bottom panel) by one-step real time RT-PCR in Chinese male never-
smokers. One sample is shown for each detected fusion variant (V1,
V2, V3a, V4a, and V5a) as indicated below the case numbers. NC,
negative case; M, DNA ladder. (B) The frequency of different EML4-ALK
variants. (C) ALK Break Apart FISH analysis showing ALK inversion in an
EML4-ALK-negative (ALK-, left) and –positive (ALK+, right) carcinoma
tissue. The inversion is indicated by two separated red and green
fluorescent dots that are used to label two probes targeting the
sequences flanking the breaking point. One such example is indicated
by a pair of arrows in ALK + image.
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green fluorescent dots) from two probes are colocalized
(merged as a yellowish signal) or less than two signal di-
ameters apart. However, when ALK rearrangement occurs,
the signals from two probes are more than two signal
diameters apart in a single nucleus (positive cell). A sam-
ple is considered negative if <5 cells out of 50 (<5/50
or <10%) are positive, positive if >25 cells out of 50
(>25/50 or >50%) are positive, or equivocal if 5 to 25 cells
(10 to 50%) are positive, which needs a further evaluation
(See vendor’s product manual for more details).
Results
Characterization of enrolled patients
To determine the frequency of EML4-ALK rearrange-
ment in a cohort of NSCLC patients who are male never-
smokers in a single ethnic group, we assembled 95
Chinese male never-smoker patients who were diag-
nosed as NSCLC from January 2012 to June 2013. The
major clinical features of these patients are summarized
in Table 1. The median age of these patients is 58.76 years
old (yrs), ranging from 38 to 76. Nearly half of the pa-
tients are at their 60s or older, while 28.42% of the pa-
tients are in their fifties and 21.05% in their forties. The
majority of the patients are diagnosed as adenocarcinoma
(84/95 or 88.4%). Only 6.32% of the patients carry squa-
mous carcinomas and 5.26% carry other types of carcin-
omas. These patients can be divided into three subgroups
based on the differentiation levels of their carcinomas
cells. The number of patients is not significantly different
among three groups with 31, 39, or 25 patients in each
group carrying poorly, moderately, or well differentiated
carcinomas, respectively.
Detection and characterization of EML4-ALK
rearrangements
FFPE samples were prepared from resected lung carcin-
omas of enrolled patients. To detect EML4-ALK re-
arrangement, we extracted total RNAs from FFPE
samples and performed one-step real time RT-PCRs
using primers that recognize all known EML4-ALK fu-
sion transcript variants. By this method, we detected
EML4-ALK translocation in 8 carcinomas, accounting for
8.42% in 95 Chinese male never-smokers with NSCLC.
We have detected a total of five different types of EML4-
ALK fusion transcript variants, as shown in the DNA gel
image (Figure 1A). These results were verified by add-
itional RT-PCR experiments using a set of previously
published primers [24]. Among 8 EML4-ALK positive
carcinomas, there are three cases (37.5%) with variant 2
(V2), two cases (25%) with V5a and one each (12.5%)
with variant V1, V3a, or V4a, respectively (Figure 1B).
The frequency of the incidence for each variant is 1.05%
for V1, V3a, or V4a, 3.16% for V2, and 2.11% for V5a inChinese male never-smokers with NSCLC (Figure 1B).
ALK rearrangements were confirmed by using the Vysis
ALK Break Apart FISH Probe Kit, which detects ALK re-
arrangements using two fluorescent-labeled probes flank-
ing the ALK breaking point. As shown in Figure 1C, ALK
rearrangements, indicated by two separated fluorescent
signals (for example, orange and green signals indicated
by a pair of arrows in the right panel) in a distance at
least two signal diameters apart in a single nucleus, are
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but not (or less frequently in some cases) in fusion-
negative carcinoma (ALK-, right panel). We further con-
firmed the identity of these RT-PCR products by DNA
sequencing. The DNA sequencing traces are shown in
Figure 2. The cartoons showing the organization of exons
from EML4 and ALK for each variant are also included in
the above mentioned figure.TG A C TG A C G AG AG A CGA CGA CGA CG A CTG A CTG A C
EML4 Exon 13 ALK Exon 20
V1 (F237)
AA G AG AG A CGA CG CCCT CT CAAA GAGAG A TCTC TTTTT
EML4 Exon 20 ALK Exon 20
V2 (B287)
AG AG AG A CGA CG CCCT CT CAA AA GA G ACCTTT TC AG
V5a (F78)
EML4 Exon 2 ALK Exon 20
V4a (B256)
AG AG AG A CGA CG CCCT CT CAAAAA GA GACCTT TT C AG
EML4 Exon 14 ALK Exon 20
EML4 Exon 6 ALK Exon 20







Figure 2 Representative DNA sequencing chromatographs and
schematic drawings showing EML4-ALK fusion junctions. Five
EML4-ALK fusion transcript variants were detected by one-step real
time RT-PCR. The DNA sequences and their sequencing traces are
shown for each detected fusion transcripts: V1 (A), V2 (B), V3a (C),
V4a (D), and V5a (E). The Case ID is also indicated for each sample.
Schematic drawings showing the organization of fusion junctions
are shown below the corresponding DNA sequences.ALK mRNA and protein are exclusively expressed in
EML4-ALK-positive carcinomas
One-step real-time RT-PCRs were performed to measure
the expression level of ALK in all 95 samples using
primers specific to ALK TK domains, which are in-
cluded in the mRNA transcribed from both intact ALK
genes and EML4-ALK fusion genes. We have found that
ALK TK mRNA level (normalized to house gene ABL)
in the EML4-ALK-positive carcinomas is significantly
higher (p < 0.0001 by Mann–Whitney test) than in the
EML4-ALK-negative samples (Figure 3). As shown in the
scatter plot, the expression level of ALK TK mRNA is
either non-detectable or at very low level. This result
suggests that the expression of ALK mRNAs is the result
of ALK translocation and that ALK mRNAs are mostly
transcribed from the EML4-ALK fusion gene, but not
from the intact ALK gene. We also performed immuno-
histochemistry using anti-ALK antibody and found that
ALK protein is highly expressed in EML4-ALK positive
samples, but not (or at very low level) in EML4-ALK
negative samples (see Figure 4A-B for representative im-
ages). As reported previously [9,26,27], we found a mu-
cinous cribriform pattern in two of EML4-ALK-positive
adenocarcinomas (Figure 4C-D). Together, these results
suggest that EML4-ALK rearrangement results in aber-
rant expression of ALK TK domain at both mRNA and
protein levels. These results are also consistent with the
notion that EML4-ALK is an oncogene, whose abnormal
ALK tyrosine kinase activity is likely responsible for the
tumorigenesis in the patients with ALK translocation.
Clinical characterization of EML4-ALK positive patients
Our results suggest that ALK rearrangements are usually
detected in younger patients. The median age of EML4-
ALK positive patients is 50.63 yrs vs. 58.88 yrs in all pa-
tients. It ranges from 40 to 69 yrs, with 5 of them at their
40s, one at 52 yrs, and two at their 60s. As listed in
Table 3, the difference in the ages between patients with
and without EML4-ALK is significant (p < 0.02 by Chi-
square test), suggesting an early-onset of NSCLC in
EML4-ALK positive patients. Among all 8 EML4-ALK
positive patients, two were diagnosed as squamous car-
cinomas (Table 4), with one at the age of 46 and one at
the age of 67. Therefore, it is hard to conclude with this
small sample size whether there is any age preference in
the disease onset in the patients with squamous carcin-
omas. In the patients with adenocarcinoma, disease onset
predominantly occurs in younger patients, with all but
one (5 vs. 1) at the age of 52 yrs and younger. Comparing
to the observation that 26 patients are 52 yrs or younger
and that 63 patients are older than 52 yrs in all the
patients with adenocarcinomas, the difference is signifi-
cant (p < 0.013, by Fisher’s exact test). This result suggests
that NSCLC onset age in Chinese male never-smokers is















































Figure 3 Expression of ALK mRNA in Chinese male never-smokers with NSCLC. The expression level of ALK mRNA in each carcinoma (total
95 specimens) was determined by one-step real time RT-PCR using primers specific to the ALK TK domain and presented as the intensity normalized
to the housekeeping gene ABL. While ALK mRNA is not expressed or expressed at very low levels in EML4-ALK negative carcinomas, it is aberrantly
expressed in all EML4-ALK positive samples. The mean intensities are displayed in the inserted bar graph for both EML4-ALK negative or positive
patients, showing a significant difference in the expression levels of the two groups. Values are means ± SEM in the insert. p value was determined
by student t test.
BA
C D
Figure 4 Representative images showing the association between ALK protein expression and carcinoma differentiation. H&E staining
and immunohistochemistry using an antibody against ALK were performed on the same FFPE tissue section from an EML4-ALK-negative (A) or an
EML4-ALK-positive (B) specimen. (A) Representative image showing the absence of any ALK protein in a well differentiated, EML4-ALK-negative
carcinoma. (B) Representative image showing the aberrant expression of ALK protein in a poorly differentiated, EML4-ALK-positive carcinoma.
(C) Representative image showing histopathology of mucinous cribriform carcinoma. (D) Representative image showing ALK immunostaining in
a section adjacent to the one shown in panel (C).
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Table 3 Distribution of EML4-ALK fusions in different age
groups





p < 0.02 by Chi-square test.
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diagnosed as adenocarcinomas.
We next examined the differentiation levels of carcin-
omas in EML4-ALK positive carcinomas. All carcinomas
except one are less-differentiated, including 4 poorly and
3 moderately differentiated cases (Table 4), suggesting
that EML4-ALK rearrangements usually occurred in less-
differentiated carcinomas. The 7 less-differentiated car-
cinomas include two moderately differentiated squamous
carcinomas, four poorly differentiated adenocarcinomas,
and one moderately differentiated adenocarcinoma. The
only well differentiated carcinoma is diagnosed as adeno-
carcinoma. Taken together, these results suggest that
EML4-ALK translocation occurs more frequently in less-
differentiated carcinomas with an early-onset in Chinese
male never-smokers with NSCLC.
Analysis of EML4-ALK in Chinese NSCLC patients
We performed an analysis using the data extracted from
6 published studies [8,14,16-18,28] that were carried out
exclusively in Chinese patients with NSCLC (Table 5).
We choose to use these data to avoid bias that may be
caused by genetic (race) and environmental (country)
differences while comparing to our analysis. By this ana-
lysis, the average frequency of EML4-ALK translocation
in non-selected Chinese patients [8,14,16-18] is 5.50%
(43/782) (Table 5), which is similar to the values esti-
mated from the patients worldwide. This analysis further
indicates that the frequency in Chinese never-smokers
(35/375 or 9.33%) is also significantly higher (p < 0.0001










*carcinomas with cribriform patterns.2.25%). By comparing to our results, the frequency of
EML4-ALK translocation is significantly higher (p < 0.01
by Fisher’s exact) in Chinese male never-smokers with
NSCLC (8/95 or 8.42%) than in all Chinese smokers
with NSCLC.
We next calculated the frequency of EML4-ALK trans-
location in male and female Chinese patients with
NSCLC regardless of smoking history (Table 5). It is sig-
nificantly higher (p < 0.002 by Fisher’s exact) in Chinese
female patients (26/272 or 9.56%) than in Chinese male
patients (14/407 or 3.44%). By comparing this to our
results, the incidence of EML4-ALK translocation in
Chinese male patients with NSCLC is significantly higher
(p < 0.048 by one-tailed Fisher’s exact) in never-smokers
(8/95 or 8.42%) than in all male patients regardless of
smoking history (14/407 or 3.44%).
Taken together, we have found that both smoking habit
and gender are associated with the frequency of EML4-
ALK translocation in Chinese NSCLC patients. It is more
frequently detected in female than in male patients and
more in never-smokers than in smokers. In Chinese male
patients with NSCLC, EML4-ALK translocation is also
more frequently detected in never-smokers than in
smokers.
Discussion
In this study, we have determined the frequency of
EML4-ALK translocation and its associated clinical fea-
tures in Chinese male never smokers with NSCLC. A
previous study has shown that the frequency of EML4-
ALK translocation in Chinese female patients with
NSCLC is higher in never-smokers. Similar to that, we
have found that the incidence in Chinese male NSCLC
patients is also significantly higher in never-smokers by
comparing to published data. Interestingly, we have also
found that these Chinese male never-smoker patients in
our study are strongly associated with younger-onset and
less-differentiated carcinomas, which are likely caused by
aberrant expression of ALK mRNA and protein.
Since EML4-ALK fusion genes were first identified as
potential driver mutations in NSCLC [7], multiple studiesChinese male never-smokers with NSCLC
Variant Size EML4 ALK
V2 177 bp E20 A20
V5a 155 bp E2 A20
V2 177 bp E20 A20
V1 185 bp E13 A20
V4a 162 bp E15 A20
V2 177 bp E20 A20
V5a 155 bp E2 A20
V3a 162 bp E6 A20
Table 5 Frequency of EML4-ALK in Chinese NSCLC Patients (extracted from 6 published studies)
Publication [ref] All Patients Never-smokers Smokers Female Male
Total EML4-ALK Total EML4-ALK Total EML4-ALK Total EML4-ALK Total EML4-ALK
No. No. (%) No. No. (%) No. No. (%) No. No. (%) No. No. (%)
Rekova et al. 2007 [8] 103 3 (2.91%)
Wong et al. 2009 [14] 266 13 (4.89%) 141 10 (7.09%) 125 3 (7.09%) 134 8 (5.97%) 132 5 (3.79%)
Zhang et al. 2010 [16] 103 12 (11.65%) 52 10 (19.23%) 51 2 (19.23%) 29 5 (17.24%) 74 7 (9.46%)
Shaozhang et al. 2012 [17] 102 8 (7.84%) 52 6 (11.54%) 50 2 (11.54%) 48 6 (12.50%) 54 2 (3.70%)
Li et al. 2013 [18] 208 7 (3.37%) 78 6 (7.69%) 130 1 (7.69%) 61 7 (11.48%) 147 0 (0.00%)
Sun et al. 2010 [28] 52 3 (5.77%)
Sum 782 43 (5.5%) 375 35 (9.33%) 356 8 (2.25%) 272 26 (9.56%) 407 14 (3.44%)
By Fisher’s exact test, the difference is significant between (i) never-smokers and smokers (p < 0.0001); (ii) Female and Male (p < 0.002).
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EML4-ALK translocation. The frequencies of EML4-ALK
may vary substantially among different publications, ran-
ging from 1.6% in a cohort of Japanese patients [15] to
11.7% in a cohort of Chinese patients [16]. The large vari-
ation is likely contributed by multiple factors, including
race, gender, smoking habit, etc. Several groups have
estimated the frequency of EML4-ALK translocation
worldwide by combining published data and found the
value at 5% [6], 3.7% [17], or 4.8% [18], respectively. The
differences among these values are caused by differences
in the selection of data sources. To exclude the influence
caused by differences in races (genetic factors) and coun-
tries (geographic, cultural, environmental, diet, etc.), and
also to better determine the influence of gender and
smoking habit in the occurrence of EML4-ALK transloca-
tion, we performed an analysis using the data extracted
from published studies that were done exclusively in
Chinese patients (Table 5) [8,14,16-18]. The average
frequency of EML4-ALK in non-selected Chinese pa-
tients is 5.50% (Table 5), which is similar to the estimated
number using published studies in the patients from
multiple countries. This result suggests that race and
country have the least effect in the occurrence of EML4-
ALK translocation in NSCLC. Interestingly, our analysis
has shown that both gender and smoking habit are im-
portant factors affecting the frequency of EML4-ALK
translocation in Chinese patients. EML4-ALK transloca-
tion is more frequent in Chinese never-smokers than in
Chinese smokers, which is consistent with the result in
patients worldwide [6]. Our analysis has also clearly
shown that the difference between Chinese male and
Chinese female patients is highly significant (p < 0.002,
Table 5).
Interestingly, a previous study has found that the fre-
quency of EML4-ALK translocation is as high as 15.2%
(5/33) in Chinese female non-smokers with NSCLC [18].
Although double the amount, it is not significantly differ-
ent (by Fisher’s exact) when compared to the frequencyin Chinese male never-smokers from our study (8.42% or
8/95). Therefore, more patients are needed to draw a
solid conclusion on whether there is a significant differ-
ence in the frequency of EML4-ALK translocation
between male and female never-smokers. In addition,
authors in this study detected zero patients with EML4-
ALK translocation in 147 Chinese male patients, includ-
ing 45 never-smokers (calculated from available data in
the paper) [18]. The failure to detect any positive cases in
male patients is likely due to the small sample size and
low frequency (3.44%, Table 5) in Chinese male patients
with NSCLC. As determined in our current study, the
frequency in Chinese male never-smokers with NSCLC
(8.42%) is significantly higher than that in all Chinese
male patients with NSCLC (2.25%, Table 5). It should be
noted that although we enrolled consecutive patients
who met our criteria, our samples are predominantly col-
lected from adenocarcinomas (88.4%), which may bias
our results and interpretations.
We have detected 5 different types of EML4-ALK vari-
ants (V1, V2, V3a, V4a, and V5a). It was the first time that
V4 was detected in Chinese NSCLC patients based on
previously published results [8,14,16-18]. Both ALK
mRNAs and proteins are highly expressed in these
EML4-ALK positive carcinomas (Figures 3 and 4), which
is consistent with the notion that EML4-ALK rearrange-
ments cause aberrant expression of EML4-ALK fusion
oncogene and overactivation of ALK tyrosine kinase,
which in turn leads to the inhibition of apoptosis and pro-
motion of tumor cell proliferation [25,29,30]. Crizotinib, a
selective inhibitor of ALK and mesenchymal epithelial
growth factor tyrosine kinases, has shown significant im-
provement in response rates and response duration in
ALK-positive patients in clinical trials [25]. Meanwhile, it
has been shown that ALK-positive patients are resistant
to EGFR TKIs [22]. It is then possible that nearly one-
tenth of male never-smokers with NSCLC (8.42%) would
likely respond to crizotinib, but not to EGFR TKIs (gefi-
tinib and erlotinib) or drugs targeting other tyrosine
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identification of EML4-ALK translocation is crucial for
predicting the resistance to EGFR TKIs and the respon-
siveness to ALK TKIs. Ultimately, it will facilitate the
planning of an effective treatment and improve the out-
come of such treatment in NSCLC.
In this study, we have identified clinical features that
are associated with EML4-ALK translocation in Chinese
male never-smokers with NSCLC. We have found that
the median age in these patients (50.63 yrs) is signifi-
cantly younger than in all studied patients (58.76 yrs).
Thus, EML4-ALK translocation in Chinese male never-
smokers is more likely to occur in younger patients. In
other words, the disease onset is much earlier in EML4-
ALK-positive patients in a subset of Chinese NSCLC
patients who are male never-smokers. A previous study
has reported that the EML4-ALK-positive lung adenocar-
cinomas are characterized as less-differentiated [31]. In
that report, the differentiation levels were determined in
11 EML4-ALK positive carcinomas, which were identified
by the same group previously [32]. While only one patient
carried the carcinomas that were well-differentiated, 10
other patients carried tumors that were poorly or moder-
ately differentiated. In line with this result, our study has
shown that EML4-ALK rearrangements are predominantly
found in carcinomas with less (poorly or moderately) dif-
ferentiated cells, with the exception of one with well dif-
ferentiated cells (Table 4). However, there is a difference
between the two studies. While all patients in our study
are never-smokers, the 11 EML4-ALK positive patients in
other study include 6 never-smokers and 5 smokers. Thus,
it is possible that the differentiation of carcinomas, regard-
less of smoking history, is associated with the expression
of EML4-ALK mutant genes. In other words, the aberrant
activity of ALK tyrosine kinase induced by EML4-ALK
translocation results in less-differentiated carcinomas,
more dangerous and aggressive types of cancers.
Conclusions
In summary, the frequency of EML4-ALK translocation
in Chinese male never-smokers with NSCLC is 8.42%,
which is significantly higher than that in all Chinese male
patients or Chinese smokers. This result suggests that
EML4-ALK translocation in Chinese male NSCLC pa-
tients is associated with smoking habits. In this subset of
NSCLC patients who are Chinese male never smokers,
EML4-ALK translocation is associated with early-onset
and less-differentiated carcinomas, which are likely
caused by the aberrant expression of ALK mRNA and
protein. These results will significantly enhance our un-
derstanding about NSCLC and facilitate disease diagnosis
and designing customized treatment plans, thus leading
to the improvement in the survival time and life quality
in the patients with EML4-ALK translocation.Abbreviations
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